GlassScriptPhysician profile
Ciara A Antolin
NPI 1740047703
$1,690.39
in general payments reported to CMS, 2019-2025
13 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $350 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.12 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $444.05 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $171.34 | 2025 | Otezla |
| Abbvie INC. | $153.54 | 2024-2025 | |
| Novo Nordisk INC | $129.61 | 2025 | Ozempic |
| Lundbeck LLC | $121.48 | 2025 | Vyepti |
| Beta Bionics, INC. | $118.77 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Phathom Pharmaceuticals, INC. | $112.53 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.12 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $110.38 | 2025 | Capvaxive |
| Glaxosmithkline, LLC. | $98.84 | 2024 | Arexvy |
| Grifols USA, LLC | $58.34 | 2024 | Prolastin-C Liquid |
| Insulet Corporation | $46.11 | 2024-2025 | Omnipod |
| Sequel Med Tech, LLC | $14.28 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciara Antolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.